{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:12:43Z","timestamp":1791475963793,"version":"4.3.4"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020521","name":"Uppsala Monitoring Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40264-025-01580-3","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:27:10Z","timestamp":1751444830000},"page":"1339-1352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Signals of Adverse Reactions to Herbal Medicines: Evidence and Document Analysis Based on a Scoping Review"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3634-0317","authenticated-orcid":false,"given":"Daniele","family":"Sartori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-655X","authenticated-orcid":false,"given":"Jeffrey K.","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3720-1274","authenticated-orcid":false,"given":"Judith S.","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1593-356X","authenticated-orcid":false,"given":"Oskar","family":"Gauffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1619-3751","authenticated-orcid":false,"given":"Sara","family":"Hedfors Vidlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-230X","authenticated-orcid":false,"given":"G. Niklas","family":"Nor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-0811","authenticated-orcid":false,"given":"Igho J.","family":"Onakpoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"1580_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fphar.2013.00177","volume":"4","author":"M Ekor","year":"2014","unstructured":"Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1580_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/mutage\/17.4.265","volume":"17","author":"VM Arlt","year":"2002","unstructured":"Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis. 2002;17(4):265\u201377.","journal-title":"Mutagenesis"},{"key":"1580_CR3","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3389\/fphar.2019.01448","volume":"10","author":"RL Savage","year":"2019","unstructured":"Savage RL, Hill GR, Barnes J, Kenyon SH, Tatley MV. Suspected hepatotoxicity with a supercritical carbon dioxide extract of Artemisia annua in grapeseed oil used in New Zealand. Front Pharmacol. 2019;10:1448.","journal-title":"Front Pharmacol"},{"issue":"10","key":"1580_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.2174\/138920008786927785","volume":"9","author":"C Ulbricht","year":"2008","unstructured":"Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab. 2008;9(10):1063\u2013120.","journal-title":"Curr Drug Metab"},{"key":"1580_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2021.101362","volume":"43","author":"M Crichton","year":"2021","unstructured":"Crichton M, Strike K, Isenring E, McCarthy AL, Marx W, Lohning A, et al. \u201cIt\u2019s natural so it shouldn\u2019t hurt me\u201d: chemotherapy patients\u2019 perspectives, experiences, and sources of information of complementary and alternative medicines. Complement Ther Clin Pract. 2021;43: 101362.","journal-title":"Complement Ther Clin Pract"},{"issue":"1","key":"1580_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12906-018-2160-6","volume":"18","author":"AN Welz","year":"2018","unstructured":"Welz AN, Emberger-Klein A, Menrad K. Why people use herbal medicine: insights from a focus-group study in Germany. BMC Complement Altern Med. 2018;18(1):92.","journal-title":"BMC Complement Altern Med"},{"issue":"5","key":"1580_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/pds.1190","volume":"15","author":"S Zaffani","year":"2006","unstructured":"Zaffani S, Cuzzolin L, Benoni G. Herbal products: behaviors and beliefs among Italian women. Pharmacoepidemiol Drug Saf. 2006;15(5):354\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1580_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-031-07275-8_2","volume-title":"Pharmacovigilance for herbal and traditional medicines: advances, challenges and international perspectives","author":"EL Lee","year":"2022","unstructured":"Lee EL, Barnes J. Prevalence of use of herbal and traditional medicines. In: Barnes J, editor. Pharmacovigilance for herbal and traditional medicines: advances, challenges and international perspectives. Cham: Springer International Publishing; 2022. p. 15\u201325."},{"issue":"2","key":"1580_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ctim.2006.06.007","volume":"15","author":"N Lynch","year":"2007","unstructured":"Lynch N, Berry D. Differences in perceived risks and benefits of herbal, over-the-counter conventional, and prescribed conventional, medicines, and the implications of this for the safe and effective use of herbal products. Complement Ther Med. 2007;15(2):84\u201391.","journal-title":"Complement Ther Med"},{"issue":"4","key":"1580_CR10","volume":"2008","author":"K Linde","year":"2008","unstructured":"Linde K, Berner MM, Kriston L. St John\u2019s wort for major depression. Cochrane Database Syst Rev. 2008;2008(4): CD000448.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1580_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1046\/j.1365-2125.1998.00715.x","volume":"45","author":"J Barnes","year":"1998","unstructured":"Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol. 1998;45(5):496\u2013500.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1580_CR12","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1111\/bcp.14726","volume":"87","author":"RC Bracchi","year":"2021","unstructured":"Bracchi RC, Tseliou F, Copeland L, Routledge PA, Thomas A, Woods F, et al. Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions. Br J Clin Pharmacol. 2021;87(8):3344\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1580_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.2042-7174.2011.00150.x","volume":"19","author":"R Walji","year":"2011","unstructured":"Walji R, Boon H, Barnes J, Welsh S, Austin Z, Baker GR. Reporting natural health product related adverse drug reactions: is it the pharmacist\u2019s responsibility? Int J Pharm Pract. 2011;19(6):383\u201391.","journal-title":"Int J Pharm Pract"},{"key":"1580_CR14","volume-title":"WHO global report on traditional and complementary medicine. 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. WHO global report on traditional and complementary medicine. 2019. Geneva: World Health Organization; 2019."},{"key":"1580_CR15","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP), Module IX: signal management (Rev 1). Amssterdam: European Medicines Agency; 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf. (Accessed 26 Jun 2025)."},{"key":"1580_CR16","unstructured":"US Food and Drug Administration. Collaborative identification, evaluation, and resolution of a newly identified safety signal (NISS). 2020. Available from: https:\/\/www.fda.gov\/media\/137475\/download. (Accessed 26 Jun 2025)."},{"key":"1580_CR17","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2147\/JMDH.S366166","volume":"15","author":"H Demeke","year":"2022","unstructured":"Demeke H, Hasen G, Sosengo T, Siraj J, Tatiparthi R, Suleman S. Evaluation of policy governing herbal medicines regulation and its implementation in Ethiopia. J Multidiscip Healthc. 2022;15:1383\u201394.","journal-title":"J Multidiscip Healthc"},{"issue":"12","key":"1580_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/0973-7847.99950","volume":"6","author":"Ajazuddin","year":"2012","unstructured":"Ajazuddin, Saraf S. Legal regulations of complementary and alternative medicines in different countries. Pharmacogn Rev. 2012;6(12):154\u201360.","journal-title":"Pharmacogn Rev"},{"key":"1580_CR19","unstructured":"European Medicines Agency. European Union herbal monograph on Ginkgo biloba L., folium. 2015. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/herbal-monograph\/final-european-union-herbal-monograph-ginkgo-biloba-l-folium_en.pdf. (Accessed 26 Jun 2025)."},{"key":"1580_CR20","unstructured":"National Center for Complementary and Integrative Health. Health information: ginkgo. 2020. Available from: https:\/\/www.nccih.nih.gov\/health\/ginkgo. (Accessed 26 Jun 2025)."},{"key":"1580_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104647","volume":"114","author":"S Thakkar","year":"2020","unstructured":"Thakkar S, Anklam E, Xu A, Ulberth F, Li J, Li B, et al. Regulatory landscape of dietary supplements and herbal medicines from a global perspective. Regul Toxicol Pharmacol. 2020;114: 104647.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1580_CR22","unstructured":"Council for International Organizations of Medical Sciences. Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII. CRC Press, Boca Raton, Florida, USA. 2010."},{"issue":"2","key":"1580_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40264-022-01258-0","volume":"46","author":"D Sartori","year":"2023","unstructured":"Sartori D, Aronson JK, Nor\u00e9n GN, Onakpoya IJ. Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: a scoping review of the global literature. Drug Saf. 2023;46(2):109\u201320.","journal-title":"Drug Saf"},{"issue":"4","key":"1580_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bcp.12746","volume":"80","author":"S Golder","year":"2015","unstructured":"Golder S, Norman G, Loke YK. Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. Br J Clin Pharmacol. 2015;80(4):878\u201388.","journal-title":"Br J Clin Pharmacol"},{"key":"1580_CR25","first-page":"85","volume":"136","author":"E Parliament","year":"2004","unstructured":"Parliament E. Directive 2004\/24\/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001\/83\/EC on the Community code relating to medicinal products for human use. OJEU L. 2004;136:85\u201390.","journal-title":"OJEU L."},{"issue":"1","key":"1580_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/bcp.12935","volume":"83","author":"JK Aronson","year":"2017","unstructured":"Aronson JK. Defining \u201cnutraceuticals\u201d: neither nutritious nor pharmaceutical. Br J Clin Pharmacol. 2017;83(1):8\u201319.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1580_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57\u201369.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"1580_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13643-020-01429-z","volume":"9","author":"D Sartori","year":"2020","unstructured":"Sartori D, Aronson JK, Onakpoya IJ. Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature. Syst Rev. 2020;9(1):180.","journal-title":"Syst Rev"},{"issue":"28\/11","key":"1580_CR29","first-page":"1","volume":"311","author":"E Parliament","year":"2004","unstructured":"Parliament E. Directive 2001\/82\/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to veterinary medicinal products. OJEUl L. 2004;311(28\/11):1\u201366.","journal-title":"OJEUl L."},{"issue":"5","key":"1580_CR30","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s43441-020-00130-6","volume":"54","author":"O Lagerlund","year":"2020","unstructured":"Lagerlund O, Strese S, Fladvad M, Lindquist M. WHODrug: a global, validated and updated dictionary for medicinal information. Ther Innov Regul Sci. 2020;54(5):1116\u201322.","journal-title":"Ther Innov Regul Sci."},{"issue":"1","key":"1580_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jphp.12831","volume":"71","author":"EA Dauncey","year":"2019","unstructured":"Dauncey EA, Irving JTW, Allkin R. A review of issues of nomenclature and taxonomy of Hypericum perforatum L and Kew\u2019s Medicinal Plant Names Services. J Pharm Pharmacol. 2019;71(1):4\u201314.","journal-title":"J Pharm Pharmacol"},{"key":"1580_CR32","unstructured":"European Medicines Agency. European Union monographs and list entries. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/herbal-medicinal-products\/european-union-monographs-list-entries. [Accessed 26 Jun 2025]."},{"issue":"12","key":"1580_CR33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1039\/c1fo10105f","volume":"2","author":"V Silano","year":"2011","unstructured":"Silano V, Coppens P, Larra\u00f1aga-Guetaria A, Minghetti P, Roth-Ehrang R. Regulations applicable to plant food supplements and related products in the European Union. Food Funct. 2011;2(12):710\u20139.","journal-title":"Food Funct"},{"key":"1580_CR34","unstructured":"The United States Pharmacopeial Convention. About the herbal medicines compendium. 2024. Available from: https:\/\/hmc.usp.org\/about\/about-the-herbal-medicines-compendium. (Accessed 26 Jun 2025)."},{"key":"1580_CR35","unstructured":"National Institutes of Health, Office of Dietary Supplements. Dietary supplements fact sheets. 2025. Available from: https:\/\/ods.od.nih.gov\/factsheets\/list-all. (Accessed 26 Jun 2025)."},{"key":"1580_CR36","doi-asserted-by":"publisher","first-page":"1428S","DOI":"10.1093\/jn\/nxy082","volume":"148","author":"JT Dwyer","year":"2018","unstructured":"Dwyer JT, Bailen RA, Saldanha LG, Gahche JJ, Costello RB, Betz JM, et al. The dietary supplement label database: recent developments and applications. J Nutr. 2018;148:1428S-S1435.","journal-title":"J Nutr"},{"key":"1580_CR37","volume-title":"American Herbal Products Association\u2019s botanical safety handbook","author":"Z Gardner","year":"2013","unstructured":"Gardner Z, McGuffin M. American Herbal Products Association\u2019s botanical safety handbook. CRC Press, Geneva, Switzerland. 2013."},{"key":"1580_CR38","unstructured":"World Health Organization. Evaluating and publicly designating regulatory authorities as WHO listed authorities: policy document. 2021. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240023444. (Accessed 26 Jun 2025)."},{"key":"1580_CR39","unstructured":"World Health Organization. Good reliance practices in the regulation of medical products: high level principles and considerations. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations, editor. WHO Technical Report Series No 1033, Annex 10. Geneva: World Health Organization; 2021: p. 237\u201358."},{"key":"1580_CR40","unstructured":"European Commission. A guideline on summary of product characteristics. 2009. Available from: https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/smpc_guideline_rev2_en_0.pdf. (Accessed 26 Jun 2025)."},{"key":"1580_CR41","unstructured":"US Food and Drug Administration. 21 Code of Federal Regulations, Part 201. 1975. Available from: https:\/\/www.ecfr.gov\/current\/title-21\/part-201. (Accessed 26 Jun 2025)."},{"key":"1580_CR42","first-page":"34","volume":"136","author":"E Parliament","year":"2004","unstructured":"Parliament E. Directive 2004\/27\/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001\/83\/EC on the community code relating to medicinal products for human use. OJEU L. 2004;136:34\u201357.","journal-title":"OJEU L."},{"key":"1580_CR43","first-page":"417","volume":"103","author":"United States Congress","year":"1994","unstructured":"United States Congress. Dietary supplement health and education Act of 1994 Public Law 103\u2013417 103rd Congress. Public Law. 1994;103:417.","journal-title":"Public Law."},{"issue":"7","key":"1580_CR44","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/pds.4446","volume":"27","author":"WN Insani","year":"2018","unstructured":"Insani WN, Pacurariu AC, Mantel-Teeuwisse AK, Gross-Martirosyan L. Characteristics of drugs safety signals that predict safety related product information update. Pharmacoepidemiol Drug Saf. 2018;27(7):789\u201396.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1580_CR45","doi-asserted-by":"crossref","unstructured":"Ripley BD. The R project in statistical computing. MSOR Connections. The newsletter of the LTSN Maths, Stats & OR Network. 2001;1(1):23\u20135.","DOI":"10.11120\/msor.2001.01010023"},{"key":"1580_CR46","volume-title":"ggplot2: elegant graphics for data analysis by Wickham, H","author":"L Wilkinson","year":"2011","unstructured":"Wilkinson L. ggplot2: elegant graphics for data analysis by Wickham, H. Oxford: Oxford University Press; 2011."},{"issue":"4","key":"1580_CR47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2018-214598","volume":"78","author":"L Arnaud","year":"2019","unstructured":"Arnaud L, Mertz P, Gavand PE, Martin T, Chasset F, Tebacher-Alt M, et al. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis. 2019;78(4):504\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1580_CR48","unstructured":"Paal T. Teucrium chamaedrys, teucrium scorodonia: hepatitis, other liver disorders. SIGNAL Document. 2006(Mar.):10\u20137"},{"key":"1580_CR49","unstructured":"Pharmaceuticals and Medical Devices Agency. Summary of investigation results: Inchinkoto for ethical use. 2014. Available from: https:\/\/www.pmda.go.jp\/files\/000153888.pdf. (Accessed 26 Jun 2025)."},{"issue":"1","key":"1580_CR50","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.yrtph.2014.06.007","volume":"70","author":"S Wechwithan","year":"2014","unstructured":"Wechwithan S, Suwankesawong W, Sornsrivichai V, McNeil EB, Jiraphongsa C, Chongsuvivatwong V. Signal detection for Thai traditional medicine: examination of national pharmacovigilance data using reporting odds ratio and reported population attributable risk. Regul Toxicol Pharmacol. 2014;70(1):407\u201312.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1580_CR51","unstructured":"Pharmaceuticals and Medical Devices Agency. Summary of investigation results: Gardenia fruit (prescription drug) and preparations containing gardenia fruit (prescription drug). 2018. Available from: https:\/\/www.pmda.go.jp\/files\/000222748.pdf. (Accessed 26 Jun 2025)."},{"key":"1580_CR52","unstructured":"Uppsala Monitoring Centre. Herbal drugs: tooth discolouration. SIGNAL Document. 2004(Jun.):11\u20132."},{"key":"1580_CR53","doi-asserted-by":"crossref","unstructured":"Fahim SM, Mishuk AU, Cheng N, Hansen R, Calder\u00f3n AI, Qian J. Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2019;18(2):145\u201352.","DOI":"10.1080\/14740338.2019.1562546"},{"issue":"3","key":"1580_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40264-015-0375-8","volume":"39","author":"M Arnaud","year":"2016","unstructured":"Arnaud M, Salvo F, Ahmed I, Robinson P, Moore N, Begaud B, et al. A method for the minimization of competition bias in signal detection from spontaneous reporting databases. Drug Saf. 2016;39(3):251\u201360.","journal-title":"Drug Saf"},{"key":"1580_CR55","unstructured":"Barnes J, van Hunsel F. Ginkgo biloba: cardiac arrhythmias. SIGNAL Document. 2020(Feb.):1\u201312."},{"key":"1580_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.eujim.2019.100934","volume":"30","author":"Y Woo","year":"2019","unstructured":"Woo Y, Hyun MK. Safety of herbal medicine for elderly patients with chronic disease in the Republic of Korea. Eur J Integr Med. 2019;30: 100934.","journal-title":"Eur J Integr Med."},{"key":"1580_CR57","unstructured":"Uppsala Monitoring Centre. Hypericum: hepatic injury. SIGNAL Document. 2000(Jul.):4\u20136."},{"key":"1580_CR58","unstructured":"Paal T. Hypericum perforatum: white blood cell disorders. SIGNAL Document. 2005(Nov.):4\u20136."},{"issue":"9","key":"1580_CR59","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00228-015-1898-8","volume":"71","author":"H Li","year":"2015","unstructured":"Li H, Deng J, Yue Z, Zhang Y, Sun H. Detecting drug-herbal interaction using a spontaneous reporting system database: an example with benzylpenicillin and qingkailing injection. Eur J Clin Pharmacol. 2015;71(9):1139\u201345.","journal-title":"Eur J Clin Pharmacol"},{"key":"1580_CR60","unstructured":"Savage RL. Hypericum: unintended pregnancy. SIGNAL Document. 2002(Mar.):31."},{"key":"1580_CR61","unstructured":"Napke E. Echinacea extract: bronchospasm. SIGNAL Document. 1999(Feb.):15."},{"key":"1580_CR62","unstructured":"Uppsala Monitoring Centre. Gingko biloba: cerebral haemorrhage. SIGNAL Document. 2001(Dec.):18."},{"key":"1580_CR63","unstructured":"Meyboom R. Gingko biloba: thrombocytopenia. SIGNAL Document. 1995(Feb.):3."},{"key":"1580_CR64","unstructured":"Meyboom R, Farah, M. Ginkgo Biloba: thrombocytopenia. SIGNAL Document. 1999(Aug.):10."},{"key":"1580_CR65","unstructured":"De Boer H, Uppsala Monitoring Centre. Pelargonium sides L\/Pelargonium reniforme L: allergic reactions. SIGNAL Document. 2005(Nov.):16\u20137."},{"key":"1580_CR66","unstructured":"European Medicines Agency, Pharmacovigilance Risk Assessment Committee. Minutes of the 13-16 May 2013 meeting. 2013. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-13-16-may-2013_en.pdf. (Accessed 26 Jun 2025)."},{"issue":"20","key":"1580_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15200","volume":"15","author":"AJ Avery","year":"2011","unstructured":"Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug reactions to the UK \u201cYellow card scheme\u201d: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1\u2013234.","journal-title":"Health Technol Assess"},{"key":"1580_CR68","unstructured":"Uppsala Monitoring Centre. Ginseng: hypertension. SIGNAL Document. 2002(Jun.):21."},{"key":"1580_CR69","unstructured":"Uppsala Monitoring Centre. Valeriana officinalis: hallucinations. SIGNAL Document. 2007(Mar.):22\u20134."},{"issue":"3","key":"1580_CR70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10298-017-1128-x","volume":"15","author":"A Es Seddiki","year":"2017","unstructured":"Es Seddiki A, Messaouidi S, Amrani R. The role of fenugreek in the occurrence of an anomaly of neural tube closure: warning signal from Morocco [in French]. Phytotherapie. 2017;15(3):155\u20138.","journal-title":"Phytotherapie."},{"issue":"10","key":"1580_CR71","first-page":"855","volume":"37","author":"S Belamalem","year":"2014","unstructured":"Belamalem S, Benkirane R, Soulaymani A, Talibi I, Ouled Errkhis R, Tebaa A, et al. Implementing the moroccan database by an automated signal detection method. Drug Saf. 2014;37(10):855.","journal-title":"Drug Saf"},{"key":"1580_CR72","doi-asserted-by":"publisher","DOI":"10.2196\/63808","volume":"10","author":"C Kongkaew","year":"2024","unstructured":"Kongkaew C, Phan DTA, Janusorn P, Mongkhon P. Estimating adverse events associated with herbal medicines using pharmacovigilance databases: systematic review and meta-analysis. JMIR Public Health Surveill. 2024;10: e63808.","journal-title":"JMIR Public Health Surveill"},{"issue":"1","key":"1580_CR73","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7861\/clinmedicine.13-1-7","volume":"13","author":"P Posadzki","year":"2013","unstructured":"Posadzki P, Watson LK, Ernst E. Adverse effects of herbal medicines: an overview of systematic reviews. Clin Med (Lond). 2013;13(1):7\u201312.","journal-title":"Clin Med (Lond)"},{"key":"1580_CR74","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-3-031-07275-8_16","volume-title":"Pharmacovigilance for herbal and traditional medicines: advances, challenges and international perspectives","author":"F van Hunsel","year":"2022","unstructured":"van Hunsel F, Gattepaille LM, Westerberg C, Barnes J. Reports for herbal medicines in the global suspected ADR database VigiBase. In: Barnes J, editor. Pharmacovigilance for herbal and traditional medicines: advances, challenges and international perspectives. Cham: Springer International Publishing; 2022. p. 279\u201390."},{"issue":"1","key":"1580_CR75","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12911-018-0599-5","volume":"18","author":"JX Wei","year":"2018","unstructured":"Wei JX, Wang J, Zhu YX, Sun J, Xu HM, Li M. Traditional Chinese medicine pharmacovigilance in signal detection: decision tree-based data classification. BMC Med Inform Decis Mak. 2018;18(1):19.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"4","key":"1580_CR76","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2165\/11586590-000000000-00000","volume":"34","author":"S Saokaew","year":"2011","unstructured":"Saokaew S, Suwankesawong W, Permsuwan U, Chaiyakunapruk N. Safety of herbal products in Thailand: an analysis of reports in the Thai health product vigilance center database from 2000 to 2008. Drug Saf. 2011;34(4):339\u201350.","journal-title":"Drug Saf"},{"issue":"3","key":"1580_CR77","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.yrtph.2014.01.013","volume":"68","author":"SH Lee","year":"2014","unstructured":"Lee SH, Shin JY, Park MJ, Park BJ. Agreement of label information of cardiovascular drugs in pregnancy among Korea, the USA, the UK, and Japan. Regul Toxicol Pharmacol. 2014;68(3):363\u20139.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"1580_CR78","first-page":"253","volume":"13","author":"BS Nikoli\u0107","year":"2013","unstructured":"Nikoli\u0107 BS, Ili\u0107 MS. Assessment of the consistency among three drug compendia in listing and ranking of drug-drug interactions. Bosn J Basic Med Sci. 2013;13(4):253\u20138.","journal-title":"Bosn J Basic Med Sci"},{"issue":"5","key":"1580_CR79","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/clpt.2014.156","volume":"96","author":"B Pfistermeister","year":"2014","unstructured":"Pfistermeister B, Sa\u00df A, Criegee-Rieck M, B\u00fcrkle T, Fromm MF, Maas R. Inconsistencies and misleading information in officially approved prescribing information from three major drug markets. Clin Pharmacol Ther. 2014;96(5):616\u201324.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1580_CR80","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/2168479018769301","volume":"53","author":"IY Cho","year":"2019","unstructured":"Cho IY, Choi KH, Sheen YY. How does \u201cRegulatory Practice\u201d create discrepancies in drug label information between Asian and Western countries? Different label information for direct oral anticoagulants approved in the United States, Europe, Korea, and Japan. Ther Innov Regul Sci. 2019;53(2):233\u201342.","journal-title":"Ther Innov Regul Sci."},{"issue":"10","key":"1580_CR81","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40264-014-0215-2","volume":"37","author":"P Warrer","year":"2014","unstructured":"Warrer P, Aagaard L, Hansen EH. Comparison of pregnancy and lactation labeling for attention-deficit hyperactivity disorder drugs marketed in Australia, the USA, Denmark, and the UK. Drug Saf. 2014;37(10):805\u201313.","journal-title":"Drug Saf"},{"issue":"3","key":"1580_CR82","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/pds.3408","volume":"22","author":"R Shimazawa","year":"2013","unstructured":"Shimazawa R, Ikeda M. Safety information in drug labeling: a comparison of the USA, the UK, and Japan. Pharmacoepidemiol Drug Saf. 2013;22(3):306\u201318.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1580_CR83","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/pds.4111","volume":"26","author":"K Jayaputra","year":"2017","unstructured":"Jayaputra K, Ono S. Differences between the United States and Japan in labels of oncological drugs. Pharmacoepidemiol Drug Saf. 2017;26(2):143\u201351.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1580_CR84","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/cpt.1167","volume":"105","author":"S Jeong","year":"2019","unstructured":"Jeong S, Kam G, Li J, Lee S, Lee H, Noh Y, et al. Assessment of consistency of drug interaction information in drug labels among the United States, the United Kingdom, China, Japan, and Korea. Clin Pharmacol Ther. 2019;105(2):505\u201314.","journal-title":"Clin Pharmacol Ther"},{"key":"1580_CR85","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.yrtph.2018.07.024","volume":"98","author":"D Yoon","year":"2018","unstructured":"Yoon D, Song I, Noh Y, Li J, Shin JY. Consistency of listed indications and contraindications between the U.S,. the U.K., Japan, and Korea on prescription drug labels. Regul Toxicol Pharmacol. 2018;98:168\u201370.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1580_CR86","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1741-7015-9-94","volume":"9","author":"DK Raynor","year":"2011","unstructured":"Raynor DK, Dickinson R, Knapp P, Long AF, Nicolson DJ. Buyer beware? Does the information provided with herbal products available over the counter enable safe use? BMC Med. 2011;9:94.","journal-title":"BMC Med"},{"issue":"2","key":"1580_CR87","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/ecc.12132","volume":"23","author":"R Pihlak","year":"2014","unstructured":"Pihlak R, Liivand R, Trelin O, Neissar H, Peterson I, Kivistik S, et al. Complementary medicine use among cancer patients receiving radiotherapy and chemotherapy: methods, sources of information and the need for counselling. Eur J Cancer. 2014;23(2):249\u201354.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1580_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-000854","volume":"2","author":"MH Khan","year":"2012","unstructured":"Khan MH, Tanimoto T, Nakanishi Y, Yoshida N, Tsuboi H, Kimura K. Public health concerns for anti-obesity medicines imported for personal use through the internet: a cross-sectional study. BMJ Open. 2012;2(3): e000854.","journal-title":"BMJ Open"},{"issue":"4","key":"1580_CR89","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ctim.2004.09.005","volume":"12","author":"A Molassiotis","year":"2004","unstructured":"Molassiotis A, Xu M. Quality and safety issues of web-based information about herbal medicines in the treatment of cancer. Complement Ther Med. 2004;12(4):217\u201327.","journal-title":"Complement Ther Med"},{"issue":"11","key":"1580_CR90","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1001\/jama.290.11.1505","volume":"290","author":"CA Morris","year":"2003","unstructured":"Morris CA, Avorn J. Internet marketing of herbal products. JAMA. 2003;290(11):1505\u20139.","journal-title":"JAMA"},{"key":"1580_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2021.102674","volume":"57","author":"JY Ng","year":"2021","unstructured":"Ng JY, Marwaha A, Ans M. The quality of information available about Ephedra sinica on online vendor websites: the Canadian consumer experience. Complement Ther Med. 2021;57: 102674.","journal-title":"Complement Ther Med"},{"key":"1580_CR92","unstructured":"Therapeutic Goods Administration. Safety review of Andrographis paniculata and anaphylactic\/allergic reactions. 2015. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/safety-review-andrographis.pdf. (Accessed 26 Jun 2025)."},{"issue":"4","key":"1580_CR93","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/bcp.13171","volume":"83","author":"G Mazzanti","year":"2017","unstructured":"Mazzanti G, Moro PA, Raschi E, Da Cas R, Menniti-Ippolito F. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol. 2017;83(4):894\u2013908.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1580_CR94","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/10755530260127943","volume":"8","author":"A Denham","year":"2002","unstructured":"Denham A, McIntyre M, Whitehouse J. Kava: the unfolding story: report on a work-in-progress. J Altern Complement Med. 2002;8(3):237\u201363.","journal-title":"J Altern Complement Med"},{"issue":"4","key":"1580_CR95","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/gme.0b013e31816054bf","volume":"15","author":"GB Mahady","year":"2008","unstructured":"Mahady GB, Dog TL, Barrett ML, Chavez ML, Gardiner P, Ko R, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause. 2008;15(4):628\u201338.","journal-title":"Menopause"},{"issue":"3","key":"1580_CR96","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11096-012-9744-x","volume":"35","author":"B Arguello","year":"2013","unstructured":"Arguello B, Fernandez-Llimos F. Worldwide analysis of factors associated with medicines compendia publishing. Int J Clin Pharm. 2013;35(3):386\u201392.","journal-title":"Int J Clin Pharm"},{"key":"1580_CR97","unstructured":"European Medicines Agency. Herbal medicinal products. Amsterdam: European Medicines Agency; 2025. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/herbal-medicinal-products. (Accessed 26 Jun 2025)."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01580-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01580-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01580-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:03:17Z","timestamp":1762840997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01580-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":97,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01580-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"18 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was part of Daniele Sartori\u2019s DPhil in Evidence-Based Medicine at the University of Oxford. The DPhil is funded by the Uppsala Monitoring Centre. The funding body exerted no undue influence on the study throughout its conduct or design. The views expressed are those of the authors and not necessarily those of the Uppsala Monitoring Centre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jeffrey K. Aronson has written and edited articles and textbooks on adverse drug reactions, including\n                      Meyler\u2019s Side Effects of Drugs\n                      (16th edition, 2016), its companion volumes the\n                      Side Effects of Drugs Annuals\n                      , and\n                      Stephens' Detection and Evaluation of Adverse Drug Reactions\n                      (6th edition, 2011). Daniele Sartori, Judith S. Brand, Oskar Gauffin, Sara Hedfors Vidlin and Igho J. Onakpoya have no conflicts of interest that are directly relevant to the content of this article. G. Niklas Nor\u00e9n is an Editorial Board member of\n                      Drug Safety\n                      . G. Niklas Nor\u00e9n was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This research relied on previously collected, anonymised, non-National Health Service data. As such, ethics approval was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Research data on the included studies in the published scoping review are available here\n                      \n                      . For the specifics of the studies in this research, please refer to the ESM.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The R code used to produce the figures is available upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"DS, IJO, NN and JKA conceptualised the study. DS undertook the data collection and analysis, and was supervised by IJO, JKA and NN. DS, JSB, OG and SHV contributed to the data visualisation and provided input for the data analysis. All authors have contributed to the original draft and to the revision of subsequent versions of the manuscript, and have read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}